791 / 1266
Conclusions
In order to make progress in pHGG, DIPG or aHGG
Biologically targeted therapies are needed
Biomarkers are required for patient selection
Accurate preclinical models needed
Extrapolation of data/ studies only possible for
Shared targets and defined molecular groups
Needs to be confirmed if these targets are relevant
in different tumour entities
e.g.
DIPG
>
pHGG
>
aHGG